Navigation Links
Innovate Biopharmaceuticals, Targeting Celiac Disease And Ulcerative Colitis, presenting at BIO CEO & Investor Conference
Date:2/8/2017

RALEIGH, N.C., Feb. 7, 2017 /PRNewswire/ -- Executives from Innovate Biopharmaceuticals Inc., which has drug candidates entering Phase 3 and Phase 2 clinical trials, respectively, for the treatments of celiac disease and ulcerative colitis, will be in New York Feb. 13-14, meeting with potential investors at the BIO CEO & Investor Conference. Innovate's presentation is on Monday, Feb. 13, at 2 p.m. EST in the Conrad Room at The Waldorf Astoria.

Interested investors and licensing partners can email the company to schedule meetings: investor.relations@innovatebiopharma.com.

Innovate is a privately held, clinical stage biotechnology company focused on developing novel autoimmune/inflammation medicines. Innovate is also developing therapeutics for unmet needs with global impact and for orphan indications.

The company's lead drug candidate for celiac disease, larazotide acetate (INN-202), begins Phase 3 clinical trials in 2017. Larazotide, a novel oral peptide, has been studied in more than 800 patients with results that consistently reduced clinical symptoms of celiac disease. Larazotide's unique mechanism of action of reducing antigen trafficking across epithelial cells makes it a promising therapeutic for multiple diseases involving "leaky tight junctions."

Innovate's second therapeutic, INN-108, enters Phase 2 trials in 2017. INN-108 is a small molecule for the treatment of an adult orphan indication and for mild to moderate ulcerative colitis.  INN-108 is a prodrug that only becomes activated in the colon. An oral liquid formulation is also in development for pediatric and elderly patients.

Licensing opportunities for these drugs are available outside the U.S.

Forward Looking Statements 
This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, which are subject to risks and uncertainties that could cause actual results to differ materially. Reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Innovate Biopharmaceuticals disclaims any obligation to update these forward-looking statements.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/innovate-biopharmaceuticals-targeting-celiac-disease-and-ulcerative-colitis-presenting-at-bio-ceo--investor-conference-300403730.html


'/>"/>
SOURCE Innovate Biopharmaceuticals Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. VisionGate Receives Strategic Investment from Trinnovate Ventures
2. Phytomer Is Given ISPA Innovate Award for Use of Filtration Garden for the Treatment of Water Waste at 2013 ISPA Conference and Expo
3. NYCEDC Announces Winners of Innovate Health Tech, Highlighting Innovation in NYCs Healthcare Sector
4. The JTB Law Group Continues to Innovate with its New Video Information Series and Vivid Legal Cartoons
5. MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East
6. PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering
7. PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website
8. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
9. PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
10. Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
11. ‘Grand Challenge’ targeting prostate lesion diagnostic imaging is launched
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2019)... ... December 03, 2019 , ... A new survey by ... Teleflex, and CONMED as the overall best medical sales companies to work for in ... survey polled over 1,200 professionals from the MedReps community to identify which medical ...
(Date:12/4/2019)... ... December 04, 2019 , ... Improved Pharma’s analytical ... amorphous materials. Additionally, their PDF Synchrotron methods provide a way to determine the ... both in regulatory and patent applications.  , The latest developments were recently shared ...
(Date:11/22/2019)... , ... November 22, 2019 ... ... engineering firm, hosted a live webinar covering a step-by-step cold chain validation ... antibody-drug conjugates, and cell therapies. Targeting complex cold chain biopharmaceutical industry leaders, ...
(Date:11/12/2019)... ... 2019 , ... REPROCELL Inc. a stem cell and drug ... to provided preclinical screening and drug sensitivity for its portfolio of oncology drugs. ... unique and genetically edited cell lines from various tumors. The data generated from ...
Breaking Biology Technology:
(Date:11/2/2019)... ... , ... In this podcast, Smith spoke about the history of his career ... The Beyond the Lab Podcast is an interview series initiated by Vanderbilt University School ... the biomedical field — and in these interviews, the alumni discuss the different facets, ...
(Date:10/30/2019)... Maine (PRWEB) , ... October 29, 2019 , ... ... and calibration verification kits, for SIEMENS ATELLICA® analyzers, Order Numbers 701sa & 704sa. ... MG, NA, PHOS, UA, UTP, and UUN. , Each VALIDATE® kit, liquid, ready-to-use, ...
(Date:10/30/2019)... ... October 30, 2019 , ... PathSensors, Inc. will ... TN from Tuesday, November 5, 2019, to Thursday, November 7, 2019. This convergence ... nuclear) and IED (explosive) threats. Delegates and experts from over 30 countries will ...
Breaking Biology News(10 mins):